Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.37 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18764834 | 0.90 | FAAH (0.42) | BRD4FAAHL3MBTL1NR1H2NR1H3 | |
| SCHEMBL6224033 | 0.88 | BRD4 (0.44) | BRD4FAAH | |
| SCHEMBL30828711 | 0.88 | BRD4 (0.44) | BRD4FAAH | |
| SCHEMBL368032 | 0.83 | CYP1A2 (0.45) | FAAHL3MBTL1NR1H2NR1H3 | |
| SCHEMBL6221657 | 0.80 | TBXA2R (0.47) | BRD4FAAHNR1H2 | |
| SCHEMBL4882674 | 0.80 | FAAH (0.40) | BRD4FAAHNR1H2NR1H3 | |
| SCHEMBL4385302 | 0.79 | TBXA2R (0.46) | BRD4FAAH | |
| SCHEMBL18765270 | 0.78 | BRD4 (0.46) | BRD4FAAHNR1H2 | |
| SCHEMBL19013506 | 0.77 | NR1H2 (0.43) | BRD4FAAHNR1H2NR1H3 | |
| SCHEMBL7473742 | 0.77 | CNR2 (0.41) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017068090-A1 | NOVEL FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017068089-A2 | NOVEL FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2017-04-27 | — | — | WO | disclosed |
| EP-1466603-A2 | Novel catechols as antimicrobial agents | Merck & Co., Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1176958-B1 | NOVEL CATECHOLS AS ANTIMICROBIAL AGENTS | MERCK & CO INC (US) | 2004-07-28 | — | — | EP | disclosed |
| US-6545015-B2 | Useful in therapy of bacterial infections, fungal infections | MERCK & CO., INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020040147-A1 | Useful in therapy of bacterial infections, fungal infections | HAMMOND MILTON L (US) | 2002-04-04 | — | — | US | disclosed |
| US-6348482-B1 | CONTROLLED RELEASE MICROBIOCIDES | MERCK & CO., INC. | 2002-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040147-A1 | Useful in therapy of bacterial infections, fungal infections | HAO1, TST, ARSA | BRD4 717/4885FAAH 259/4885L3MBTL1 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.